Medical diagnostic company Shimadzu Medical Systems USA reported on Monday the receipt of the US FDA 510(k) clearance for the patient side conventional radiographic/fluoroscopic (RF) table system, FLUOROspeed X1.
With immediate market launch, the company's new radiographic/fluoroscopic (RF) FLUOROspeed X1 table system offers a high image quality and a multitude of features that improve work flow and operator efficiencies which contributes to lower cost of care.
A part of the FLUOROspeed series, the company's new FLUOROspeed X1 with its 665lb static patient weight and 500lb all motion weight, easily performs both bariatric and routine daily fluoroscopic and radiographic exams. It is practically priced and comes equipped with a 17"x17" dynamic digital X-ray detector (FPD) in the table bucky allowing be used for both fluoroscopy as well as radiographic exams.
The 31.5-inch aperture opening between table top and deck also provides access for imaging patients in wheelchairs as well as fits in smaller rooms. Adding the second X-ray tube on an overhead rail, the FLUOROspeed X1's functionality and versatility increases exponentially, concluded the company.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval